These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8337146)

  • 1. Prevention and treatment of acute GvHD--new modalities.
    Hervé P
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):295-7. PubMed ID: 8337146
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
    Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of an anti-interleukine 2 receptor monoclonal antibody for GvHD prophylaxis in unrelated bone marrow transplantation. GEGMO Group.
    Belanger C
    Bone Marrow Transplant; 1993; 11 Suppl 1():112-3. PubMed ID: 8448532
    [No Abstract]   [Full Text] [Related]  

  • 4. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
    Hiscott A; McLellan DS
    Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
    Hervé P; Racadot E; Wijdenes J; Flesch M; Tiberghien P; Bordigoni P; Holler E; Powles M; Bourdeau M; Wilmer E
    Bone Marrow Transplant; 1991; 7 Suppl 2():149. PubMed ID: 1878688
    [No Abstract]   [Full Text] [Related]  

  • 6. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation.
    Holler E; Kolb HJ; Hintermeier-Knabe R; Mittermüller J; Thierfelder S; Kaul M; Wilmanns W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1234-6. PubMed ID: 8442099
    [No Abstract]   [Full Text] [Related]  

  • 8. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation.
    Fay JW; Nash RA; Wingard JR; Przepiorka D; Collins RH; Anasetti C; Devine SM; Piñeiro LA; Storb RF; Aro RM
    Transplant Proc; 1995 Feb; 27(1):1374. PubMed ID: 7533383
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.
    Tiley C; Powles R; Teo CP; Treleaven J; Findlay M; Hewetson M
    Bone Marrow Transplant; 1991; 7 Suppl 2():151. PubMed ID: 1652326
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
    Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease.
    Tse JC; Moore TB
    Pharmacotherapy; 1998; 18(5):988-1000. PubMed ID: 9758310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GVHD: overview on pathophysiology, incidence, clinical and biological features.
    Klingebiel T; Schlegel PG
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S45-9. PubMed ID: 9630325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT.
    Belanger C; Esperou-Bourdeau H; Bordigoni P; Jouet JP; Souillet G; Milpied N; Troussard X; Kuentz M; Herve P; Reiffers J
    Bone Marrow Transplant; 1993 Apr; 11(4):293-7. PubMed ID: 8485477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.
    Khoury H; Trinkaus K; Zhang MJ; Adkins D; Brown R; Vij R; Goodnough LT; Ma MK; McLeod HL; Shenoy S; Horowitz M; Dipersio JF
    Biol Blood Marrow Transplant; 2003 Nov; 9(11):714-21. PubMed ID: 14652855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.